Cargando…
Heterocyclic compounds as key structures for the interaction with old and new targets in Alzheimer’s disease therapy
Nowadays, Alzheimer’s disease (AD) is widely recognized as a real social problem. In fact, only five drugs are FDA approved for the therapy of this widespread neurodegenerative disease, but with low results so far. Three of them (rivastigmine, donepezil and galantamine) are acetylcholinesterase inhi...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5607816/ https://www.ncbi.nlm.nih.gov/pubmed/28966636 http://dx.doi.org/10.4103/1673-5374.213541 |